Skip to main content
SpringerLink
Log in

Cannabis and Recovery in Schizophrenia

  • Chapter
  • First Online:
Schizophrenia Treatment Outcomes

  • 2255 Accesses

Abstract

In this chapter, we will explore the nuanced topic of cannabis and recovery in schizophrenia. Addressing this demands knowledge of what cannabis is and a broader understanding of how it relates to schizophrenia. Therefore, we will first explore the composition of cannabis before considering its role in causality and relate this to the question of why it is used so prevalently in those suffering from this condition. From this platform, we will then review and compare recovery-based interventions. Ultimately, the conflicted nature of cannabis will be considered with attention paid to its potential role in the treatment of schizophrenia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. McLoughlin BC, Pushpa-Rajah JA, Gillies D, Rathbone J, Variend H, Kalakouti E, et al. Cannabis and schizophrenia. Cochrane Database Syst Rev. 2014;(10):CD004837. https://doi.org/10.1002/14651858.CD004837.pub3.

  2. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry. 2001;178:101–6.

    Article  Google Scholar 

  3. Mendelson JH. Marijuana. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York: Raven Press; 1987. p. 1565–8.

    Google Scholar 

  4. Gold MS. Marijuana. In: Miller NS, editor. Comprehensive handbook of alcohol and drug addiction. New York: Marcel Decker; 1991. p. 353–76.

    Google Scholar 

  5. Schwartz RH. Heavy marijuana use and recent memory impairment. In: Nahas GG, Latour C, editors. Physiopathology of illicit drugs: cannabis, cocaine, opiates. Oxford: Pergamon Press; 1991. p. 13–21.

    Google Scholar 

  6. World Health Organization. Programme on substance abuse. Cannabis: a health perspective and research agenda. [Accessed 22 June 2017.] Available at: http://apps.who.int/iris/bitstream/10665/63691/1/WHO_MSA_PSA_97.4.pdf.

  7. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA. 2002;287(9):1123–31. https://doi.org/10.1001/jama.287.9.1123.

    Article  PubMed  Google Scholar 

  8. Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, et al. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev. 1986;38(1):21–43.

    PubMed  Google Scholar 

  9. Borini P, Cardoso Guimarães R, Bicalho Borini S. Possible hepatotoxicity of chronic marijuana usage. Sao Paulo Med J. 2004;122(3):110–6. https://doi.org/10.1590/S1516-31802004000300007.

    Article  PubMed  Google Scholar 

  10. Maykut MO. Health consequences of acute and chronic marihuana use. Prog Neuro-Psychopharmacol Biol Psychiatry. 1985;9(3):209–38. https://doi.org/10.1016/0278-5846(85)90085-5.

    Article  Google Scholar 

  11. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990;87(5):1932–6.

    Article  Google Scholar 

  12. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev. 2003;83(3):1017–66. https://doi.org/10.1152/physrev.00004.2003.

    Article  PubMed  Google Scholar 

  13. Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr Bull. 2005;31(3):608–12. https://doi.org/10.1093/schbul/sbi027.

    Article  Google Scholar 

  14. Deepak C, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29(8):1558–72. https://doi.org/10.1038/sj.npp.1300496.

    Article  Google Scholar 

  15. Linszen D, van Amelsvoort T. Cannabis and psychosis: an update on course and biological plausible mechanisms. Curr Opin Psychiatry. 2007;20(2):116–20. https://doi.org/10.1097/YCO.0b013e32803577fb.

    Article  PubMed  Google Scholar 

  16. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism. Science. 1997;276(5321):2048–50. https://doi.org/10.1126/science.276.5321.2048.

    Article  PubMed  Google Scholar 

  17. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325(7374):1212–3. https://doi.org/10.1136/bmj.325.7374.1212.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Bloomfield MAP, Morgan CJA, Kapur S, Curran HV, Howes OD. The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study. Psychopharmacology. 2014;231(11):2251–9. https://doi.org/10.1007/s00213-014-3523-4.

    Article  PubMed  Google Scholar 

  19. Lee MC, Ploner M, Wiech K, Bingel U, Wanigasekera V, Brooks J, et al. Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain. 2013;154(1):124–34. https://doi.org/10.1016/j.pain.2012.09.017.

    Article  PubMed  PubMed Central  Google Scholar 

  20. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 2002;156(4):319–27.

    Article  Google Scholar 

  21. Zammit S, Moore THM, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry. 2008;193(5):357–63. https://doi.org/10.1192/bjp.bp.107.046375.

    Article  PubMed  Google Scholar 

  22. Hides L, Dawe S, Kavanagh DJ, Young RM. Psychotic symptom and cannabis relapse in recent-onset psychosis. Br J Psychiatry. 2006;189(2):137–43. https://doi.org/10.1192/bjp.bp.105.014308.

    Article  PubMed  Google Scholar 

  23. Martinez-Arevalo MJ, Calcedo-Ordoñez A, Varo-Prieto JR. Cannabis consumption as a prognostic factor in schizophrenia. Br J Psychiatry. 1994;164(5):679–81.

    Article  Google Scholar 

  24. Caspari D. Cannabis and schizophrenia: results of a follow-up study. Eur Arch Psychiatry Clin Neurosci. 1999;249(1):45–9.

    Article  Google Scholar 

  25. Degenhardt L, Tennant C, Gilmour S, Schofield D, Nash L, Hall W, et al. The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychol Med. 2007;37(7):927–34. https://doi.org/10.1017/S0033291707009956.

    Article  PubMed  Google Scholar 

  26. Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res. 2004;66(2–3):125–35.

    Article  Google Scholar 

  27. Grech A, Van Os J, Jones PB, Lewis SW, Murray RM. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry. 2005;20(4):349–53. https://doi.org/10.1016/j.eurpsy.2004.09.013.

    Article  PubMed  Google Scholar 

  28. Stirling J, Lewis S, Hopkins R, White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-op. Schizophr Res. 2005;75(1):135–7. https://doi.org/10.1016/j.schres.2004.10.006.

    Article  PubMed  Google Scholar 

  29. Horcajadas FA, Sánchez Romero S, Padín CJ. Relevance of drug use in clinical manifestations of schizophrenia. Actas Esp Psiquiatr. 2002;30(2):65–73.

    Google Scholar 

  30. Brunette MF, Dawson R, O’Keefe CD, Narasimhan M, Noordsy DL, Wojcik J, et al. A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia. J Dual Diagn. 2011;7(1–2):50–63. https://doi.org/10.1080/15504263.2011.570118.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Akerele E, Levin FR. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. Am J Addict. 2007;16(4):260–8. https://doi.org/10.1080/10550490701389658.

    Article  PubMed  Google Scholar 

  32. van Nimwegen L, de Haan L, van Beveren N, Laan W, van de Brink W, Linszen D. Subjective Well-being and craving for cannabis in first psychosis, a randomized double blind comparison of olanzapine vs risperidone. Can J Psychiatr. 2008;53(6):400–5.

    Article  Google Scholar 

  33. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2(3):e94. https://doi.org/10.1038/tp.2012.15.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Seillier A, Advani T, Cassano T, Hensler JG, Giuffrida A. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. Int J Neuropsychopharmacol. 2010;13(3):373–86. https://doi.org/10.1017/S146114570999023X.

    Article  PubMed  Google Scholar 

  35. Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC. Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci. 1998;63(1):PL1–6.

    Article  Google Scholar 

  36. Meltzer HY, Arvanitis L, Bauer D, Rein W, Meta-Trial Study Group. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry. 2004;161(6):975–84. https://doi.org/10.1176/appi.ajp.161.6.975.

    Article  PubMed  Google Scholar 

  37. GW Pharmaceuticals PLC. Filing.pdf. [Accessed 22 June 2017]. Available at: http://files.shareholder.com/downloads/AMDA-1TW341/3820052091x0xS1144204-15-55185/1351288/filing.pdf.

Download references

Author information

Authors and Affiliations

  1. NHS, Nottinghamshire, UK

    Benjamin McLoughlin

Authors
  1. Benjamin McLoughlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin McLoughlin .

Editor information

Editors and Affiliations

  1. Lawson Health Research Institute, Western University Lawson Health Research Institute, London, ON, Canada

    Amresh Shrivastava

  2. Lokmanya Tilak Municipal Medical College, De Sousa Foundation, Mumbai, India

    Avinash De Sousa

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

McLoughlin, B. (2020). Cannabis and Recovery in Schizophrenia. In: Shrivastava, A., De Sousa, A. (eds) Schizophrenia Treatment Outcomes. Springer, Cham. https://doi.org/10.1007/978-3-030-19847-3_6

Download citation

Publish with us

Policies and ethics

Search

Navigation